GLPwatch
Pipeline (9)
Investigational GLP-1 and co-agonist molecules in development. Trial counts are from ClinicalTrials.gov; click through for the molecule's trials and research.
| Molecule | Mechanism | Sponsor | Trials |
|---|---|---|---|
| Amycretin | Amylin and GLP-1 receptor co-agonist | Novo nordisk | 1 |
| Cagrilintide | Long-acting amylin analogue | Novo nordisk | 19 |
| Danuglutide | GLP-1 receptor agonist | — | 0 |
| Ecnoglutide | GLP-1 receptor agonist | — | 4 |
| Mazdutide | GLP-1 and glucagon receptor dual agonist | Eli lilly | 4 |
| Orforglipron | Oral non-peptide GLP-1 receptor agonist | Eli lilly | 28 |
| Pemvidutide | GLP-1 and glucagon receptor dual agonist | Altimmune | 5 |
| Retatrutide | GIP, GLP-1 and glucagon receptor triple agonist | Eli lilly | 17 |
| Survodutide | Glucagon and GLP-1 receptor dual agonist | Boehringer ingelheim | 18 |